Belimumab — Membership Pricing

Other medications in Rheumatology

• Canakinumab
• Deucravacitinib
• Etanercept
• Filgotinib
• Guselkumab
• Ixekizumab
• Mycophenolate
• Probenecid

About Belimumab

Belimumab is a groundbreaking biologic medication offering hope to individuals living with systemic lupus erythematosus and lupus nephritis. While its specialized nature often comes with a high price tag, TheDrugClub is committed to making vital treatments like belimumab more accessible. Our membership program aims to alleviate financial burdens, helping you manage your condition with greater peace of mind.

Belimumab, often known by its brand name Benlysta, is a targeted therapy specifically designed to treat active systemic lupus erythematosus (SLE) and active lupus nephritis in adults and children. SLE is a chronic autoimmune disease where the immune system mistakenly attacks healthy tissues, leading to widespread inflammation and tissue damage. Lupus nephritis, a serious complication of SLE, involves inflammation of the kidneys, which can impair their ability to filter waste from the blood.

This innovative medication works by targeting a specific protein called B-lymphocyte stimulator (BLyS). BLyS is crucial for the survival of B cells, a type of white blood cell that, in lupus, can overproduce harmful autoantibodies. By binding to and inhibiting BLyS, belimumab helps to reduce the number of abnormal B cells and, consequently, decreases the production of these autoantibodies. This action helps to calm the overactive immune system, reduce disease activity, and prevent further organ damage, offering a significant improvement in the quality of life for many patients.

As a biologic medication, belimumab typically comes with a substantial cost. Without insurance or significant discounts, the price for a single dose can range from thousands to tens of thousands of dollars per month, depending on the dosage, administration method (intravenous infusion or subcutaneous injection), and pharmacy. These high costs can be a major barrier for patients needing long-term treatment, making it challenging to adhere to their prescribed regimen and manage their condition effectively.

This is where TheDrugClub steps in. As a member, you gain access to our network of pharmacies and negotiated pricing, which can lead to significant savings on specialty medications like belimumab. While we cannot guarantee full coverage, our program focuses on securing substantial discount pricing for our members. Depending on your specific plan and our current agreements, you may also benefit from active-formulary benefits

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Belimumab is approved for (FDA label)

BENLYSTA is indicated for the treatment of patients 5 years of age and older with: • Active systemic lupus erythematosus (SLE) who are receiving standard therapy, and • Active lupus nephritis who are receiving standard therapy. Limitations of Use The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system (CNS) lupus. Use of BENLYSTA is not recommended in this situation.

Source: Read the full FDA label on DailyMed. Label effective date: August 21, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Belimumab (FDA label)

Intravenous Infusion For injection: 120 mg or 400 mg of belimumab as a lyophilized powder in single‑dose vials for reconstitution and dilution prior to intravenous infusion. Subcutaneous Injection Injection: 200 mg/mL of belimumab as a clear to opalescent and colorless to pale yellow solution in a single-dose prefilled autoinjector or a single-dose prefilled glass syringe. • Intravenous Infusion (for injection): 120 mg or 400 mg of belimumab lyophilized powder in single‑dose vial for reconstitution and dilution prior to intravenous infusion. ( 3 ) • Subcutaneous Injection (injection): 200 mg/mL of belimumab in single‑dose prefilled autoinjector or single‑dose prefilled syringe. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 2fa3c528-1777-4628-8a55-a69dae2381a3. SPL document ID: eb71b011-8919-478c-bed7-b94709fcd596. Label effective date: August 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Belimumab (FDA label)

The following serious adverse reactions are described below and in the Warnings and Precautions section: • Serious Infections [see Warnings and Precautions ( 5.1 )] • Hypersensitivity Reactions, including Anaphylaxis [see Warnings and Precautions ( 5.2 )] • Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis [see Warnings and Precautions ( 5.3 )] • Depression and Suicidality [see Warnings and Precautions ( 5.4 )] • Malignancy [see Warnings and Precautions ( 5.5 )] Common adverse reactions (≥5%): nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, and injection site reactions (subcutaneous administration). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-877-423-6597 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 2fa3c528-1777-4628-8a55-a69dae2381a3. SPL document ID: eb71b011-8919-478c-bed7-b94709fcd596. Label effective date: August 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Belimumab (FDA label)

BENLYSTA is contraindicated in patients with a prior history of: • Anaphylaxis with belimumab [see Warnings and Precautions ( 5.2 )]. • Stevens-Johnson syndrome or toxic epidermal necrolysis with belimumab [see Warnings and Precautions ( 5.3 )]. Previous anaphylaxis, Stevens‑Johnson syndrome, or toxic epidermal necrolysis as a reaction to belimumab. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 2fa3c528-1777-4628-8a55-a69dae2381a3. SPL document ID: eb71b011-8919-478c-bed7-b94709fcd596. Label effective date: August 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Belimumab (FDA label)

• Serious Infections: Serious and sometimes fatal infections have occurred in patients receiving immunosuppressive agents, including BENLYSTA. Use with caution in patients with severe or chronic infections. Consider interrupting therapy with BENLYSTA if patients develop a new infection during treatment with BENLYSTA. ( 5.1 ) • Progressive Multifocal Leukoencephalopathy (PML): Evaluate patients with new-onset or deteriorating neurological signs and symptoms for PML. If PML is suspected, immunosuppressant therapy, including BENLYSTA, must be suspended until PML has been excluded.

Source: FDA prescribing information (DailyMed). Set ID: 2fa3c528-1777-4628-8a55-a69dae2381a3. SPL document ID: eb71b011-8919-478c-bed7-b94709fcd596. Label effective date: August 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Belimumab (FDA label)

Formal drug interaction studies have not been performed with BENLYSTA. In clinical trials, BENLYSTA was administered concomitantly with other drugs, including corticosteroids, antimalarials, immunomodulatory and immunosuppressive agents (including azathioprine, cyclophosphamide, methotrexate, and mycophenolate), angiotensin pathway antihypertensives, HMG‑CoA reductase inhibitors (statins), and/or non-steroidal anti-inflammatory drugs (NSAIDs) without evidence of a clinically meaningful effect of these concomitant medications on belimumab pharmacokinetics. The effect of belimumab on the pharmacokinetics of other drugs has not been evaluated [see Clinical Pharmacology ( 12.3 )] .

Source: FDA prescribing information (DailyMed). Set ID: 2fa3c528-1777-4628-8a55-a69dae2381a3. SPL document ID: eb71b011-8919-478c-bed7-b94709fcd596. Label effective date: August 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.